Ascendis Pharma A/S Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $845.1M+124.5% YoYTTM through 31 Dec 2025
Net Income -$267.6MTTM through 31 Dec 2025
Free Cash Flow $60.4MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 86.8% |
| Operating Margin | -18.9% |
| Net Margin | -31.7% |
Returns
139.9%ROE
-17.5%ROA
Balance Sheet Health
Debt / Equity-3.90x
Current Ratio1.04x
Net Debt$130.2M
Cash & Equivalents$616M
Quality Metrics
Piotroski F-Score5 / 9
FCF Margin7.2%
Multi-Year Trend
RevenueFY2025: $720.1M
Diluted EPSFY2025: $-3.76
Dividend
No dividend
Capital Allocation
Capex Intensity0.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| YORVIPATH (palopegteriparatide) | $477M | View detailsRobust commercial momentum ex-US with availability in more than 30 countries commercially or through named patient programs. | |
| SKYTROFA (lonapegsomatropin) | $206M | View detailsSolid brand performance reflecting sustained value in growth disorders. |
Financials converted at 0.8513 from EUR.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.